Replies to post #690713 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

Do the maths yourself.
For the NICE to grant prescription status for DCVAX-L, for every 100 treatments reimbursed to Advent, not NWBO, the Health Economist would have to knowingly allow the NHS to absorb a repeated QALY loss of £21.7 million to the NHS budget.

Here’s some beans to grow a magic money tree. 🫘